Virtual Library
Start Your Search
Hao Sun
Author of
-
+
P1.01 - Advanced NSCLC (Not CME Accredited Session) (ID 933)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
-
+
P1.01-99 - Detecting HER2 Alterations by Next Generation Sequencing (NGS) in Patients with Advanced NSCLC from the United States and China (ID 11285)
16:45 - 18:00 | Author(s): Hao Sun
- Abstract
Background
Advances in NGS have led to an increase in identifying specific actionable gene alterations across tumor types. We collected data on HER2 gene alterations detected by NGS from patients with advanced NSCLC and analyzed clinical characteristics and HER2 targeted treatments.
a9ded1e5ce5d75814730bb4caaf49419 Method
Patients diagnosed with advanced NSCLC and underwent NGS testing from Jun 2014 to Dec 2017 at Memorial Sloan-Kettering Cancer Center (MSK) and Guangdong General Hospital (GGH) were included. NGS platforms were MSK-IMPACTTM in MSK and GeneSeek or BurnStone in GGH. Descriptive statistics are used in data analysis.
4c3880bb027f159e801041b1021e88e8 Result
2200 patients from MSK and 490 patients from GGH underwent NGS testing. HER2 mutation and/or amplification were detected in 91/2200(4.1%) patients and 28/490(5.7%) patients from MSK and GGH respectively. Clinical characteristics were listed in Table1. 37.4%(34/91) and 21.4%(6/28) patients from MSK and GGH received HER2 targeted therapies. More patients were enrolled to HER2 inhibitors clinical trials in MSK(24.2%) than GGH(7.1%). The characteristics of HER2 alterations are summarized in Table2.
Table 1. Comparison of HER2 alterations in advanced NSCLC patients from U.S. and China
MSK
N (%)
GGH
N (%)
Total Patients
91
28
Age at Diagnosis (years)
<=60
34 (37.4%)
13 (46.4%)
>60
57 (62.6%)
15 (53.6%)
Sex
Male
37 (40.7%)
14 (50%)
Female
54 (59.3%)
14 (50%)
Smoking History
Former/Current Smoker
53 (58.2%)
7 (25%)
Non-Smoker
38 (41.8%)
21 (75%)
Histology
Adenocarcinoma
84 (92.3%)
25 (89.3%)
Squamous Cell Carcinoma
5 (5.5%)
0
Misc
2 (2.2%)
3 (10.7%)
HER2 status
Mutation
48 (52.7%)
16 (57.1%)
Amplification
32 (35.2%)
11 (39.3%)
Mutation + Amplification
11 (12.1%)
1 (3.6%)
HER2 targeted treatment
34 (37.4%)
6 (21.4%)
Enrolled to HER2 inhibitors clinical trials
22 (24.2%)
2 (7.1%)
8eea62084ca7e541d918e823422bd82e ConclusionTable 2. HER2 alteration in advanced NSCLC patients from U.S. and China combined
NGS Result
Mutation Only
N (%)
Amplification Only
N (%)
Mutation + Amplification
N (%)
Total Patients 64 43 12 Age at Diagnosis (years)
<=60
31 (48.4%)
20 (46.5%)
8 (66.7%)
>60
33 (51.6%)
23 (35.9%)
4 (33.3%)
Sex
Male
39 (60.9%)
19 (44.2%)
7 (58.3%)
Female
25 (39.1%)
24 (55.8%)
5 (41.7%)
Smoking History
Former/Current Smoker
31 (48.4%)
24 (55.8%)
5 (41.7%)
Non-Smoker
33 (51.6%)
19 (44.2%)
7 (58.3%)
Histology
Adenocarcinoma
58 (90.6%)
39 (90.7%)
12 (100%)
Squamous Cell Carcinoma
1 (1.6%)
4 (9.3%)
0
Misc
5 (7.5%)
0
0
HER2 targeted treatment
Yes
19 (29.7%)
14 (32.6%)
7 (58.3%)
No
45 (70.3%)
29 (67.4%)
5 (41.7%)
The incidence and clinical characteristics of HER2 alterations in advanced NSCLC were similar between two large cancer centers in the U.S. and China. These data support U.S.-China collaboration in clinical trials for patients with rare molecular subsets of NSCLC to accelerate new cancer drug development.
6f8b794f3246b0c1e1780bb4d4d5dc53